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Abstract
Background: HIV-infected infants have high risk of death in the first two years of life if untreated. WHO guidelines
recommend early infant HIV diagnosis (EID) of all HIV-exposed infants and immediate antiretroviral therapy (ART) in HIV-
infected children under 24-months. We assessed the cost-effectiveness of this strategy in HIV-exposed non-breastfed
children in Thailand.
Methods: A decision analytic model of HIV diagnosis and disease progression compared: EID using DNA PCR with
immediate ART (Early-Early); or EID with deferred ART based on immune/clinical criteria (Early-Late); vs. clinical/serology
based diagnosis and deferred ART (Reference). The model was populated with survival and cost data from a Thai
observational cohort and the literature. Incremental cost-effectiveness ratio per life-year gained (LYG) was compared against
the Reference strategy. Costs and outcomes were discounted at 3%.
Results: Mean discounted life expectancy of HIV-infected children increased from 13.3 years in the Reference strategy to
14.3 in the Early-Late and 17.8 years in Early-Early strategies. The mean discounted lifetime cost was $17,335, $22,583 and
$29,108, respectively. The cost-effectiveness ratio of Early-Late and Early-Early strategies was $5,149 and $2,615 per LYG,
respectively as compared to the Reference strategy. The Early-Early strategy was most cost-effective at approximately half
the domestic product per capita per LYG ($4,420 in Thailand 2011). The results were robust in deterministic and probabilistic
sensitivity analyses including varying perinatal transmission rates.
Conclusion: In Thailand, EID and immediate ART would lead to major survival benefits and is cost- effective. These findings
strongly support the adoption of WHO recommendations as routine care.
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Introduction
In 2011, there were an estimated 330,000 infants newly infected
with HIV through mother-to-child transmission (MTCT), over
90% of whom were in sub-Saharan Africa and Asia [1]. Without
antiretroviral therapy (ART), up to 50% will die by two years of
age, in resource limited settings [2,3]. The scale up of ART has
dramatically reduced HIV-related mortality in children [4–6].
However, the risk of early mortality on ART remains high among
infants initiating therapy after presenting with symptoms or
immunosuppression, with 14% to 27% deaths during the first
year of therapy [7–9]. The landmark CHER trial in South Africa,
which randomized asymptomatic HIV-infected infants with
CD4.25% (at median of 7 weeks old) to immediate or deferred
ART based on WHO 2006 clinical and immune criteria, reported
a 76% reduction in mortality and 75% reduction in disease
progression in the immediate ART strategy [10]. The WHO
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guidelines were subsequently revised in 2008 to recommend
immediate ART in all HIV-infected infants under 12-months,
irrespective of clinical or immune status [11]. In 2010, this was
extended to all HIV-infected children under 2-years [12] and in
2013, to all under 5-years [13].
Early initiation of ART during infancy, when risk of mortality is
highest, requires access to early infant HIV diagnosis (EID) based
on virologic assays (e.g. DNA PCR or RNA assays) rather than
standard serology tests due to persistence of maternal anti-HIV
antibodies for up to 18-months [11]. This requires access to a
specialised laboratory and trained technicians. In 2011, it was
estimated that only 28% of HIV-exposed infants in resource
limited countries received EID within the first two months of life,
as per recommendations [14], and coverage of ART among
children eligible for treatment remains disproportionately low at
28% as compared to 57% among adults [1].
As part of the UN Global plan for the virtual elimination of
paediatric AIDS through the scale up of prevention of MTCT
(PMTCT) services, there is an urgent need to improve access to
EID and ensure timely provision of ART in HIV-infected
children. To date there are no data on the cost-effectiveness of
early HIV diagnosis and treatment strategies in children in
resource-limited settings to inform donors and policy makers
facing competing public health demands.
This study examines the cost-effectiveness of EID of HIV-
exposed infants and immediate ART of HIV-infected children
under 24-months in the Thai setting. Thailand was one of the first
middle-income countries to pilot a national EID programme from
2007 [15].
Methods
We examined the cost-effectiveness, from the health care
provider’s perspective, of: (i) EID of HIV-exposed infants using
DNA PCR and immediate ART in HIV infected children ,24-
months (Early-Early); (ii) EID and deferred ART based on clinical
and immune criteria (Early-Late); as compared to (iii) clinical
based diagnosis and serology at 18-months with deferred initiation
of ART based on clinical and immune criteria (Reference). The
reference strategy represented standard of care in Thailand up to
2007 and reflects the current status in many resource-limited
settings without access to EID. The Early-Late strategy represent-
ed the intermediate stage where EID is provided but with deferred
ART as per 2008 WHO guidelines, before the results of the
CHER trial [16]. This reflects current practice in some settings
expanding EID, where immediate ART is not implemented due to
poor referral systems or lack of readiness of parents/caregivers
[17]. The Early-Early strategy reflects the 2010 WHO recom-
mendations for best practice [12]. This is similar to current Thai
guidelines which recommend EID and immediate ART in HIV
infected children ,12-months irrespective of immune/clinical
status, although this has not yet been extended to all children ,24
months [18].
Figure 1. Decision tree for HIV diagnosis and treatment strategies.
doi:10.1371/journal.pone.0091004.g001
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Model Overview
We developed a cohort simulation model that incorporates data
on perinatal transmission, natural history of HIV disease,
treatment efficacy and cost of care from Thailand. The model
was composed of a decision tree and a Markov model. The
decision tree (Figure 1) presents the diagnostic component of the
intervention and includes all HIV-exposed infants. The Markov
model (Figure 2) presents the ART component of the intervention
and includes only HIV-infected children initiated on therapy.
Based on the current estimates in Thailand, we assumed a
hypothetical cohort of 6,000 children born from HIV-infected
mothers per year [14].
Decision Tree
HIV-exposed children entered the decision tree at birth with a
probability of HIV infection through in-utero or intra-partum
transmission. Post-partum transmission through breastfeeding was
not considered as Thailand has very high coverage of formula
feeding for this population.
Early HIV diagnosis was provided using DNA PCR on dried
blood spots (DBS) with an assumed 100% sensitivity and specificity
[19]. In the Early-Early and Early-Late strategies HIV-exposed
children had probabilities of routine EID at 6–8 weeks of age, with
confirmation EID as soon as possible in children who test positive
(within one month). Among children who tested negative, the
second confirmation test was conducted at 4 months [18]. HIV-
infected children with confirmed diagnosis had monthly proba-
bilities of: linkage to HIV care and initiation of ART (as per
criteria in each strategy) or pre-ART death.
In the reference strategy, HIV-infected children had monthly
probabilities of developing HIV symptoms; clinical diagnosis if ,
18-months and serology thereafter; routine serology test at 18-
months; initiation of ART based on clinical criteria or pre-ART
death. Due to incomplete coverage of EID and linkage to HIV
care, a proportion of HIV-infected children in the early diagnosis
strategies would revert to the reference strategy with probabilities
of disease progression and clinical based diagnosis but with access
to EID for confirmation of HIV-infection if ,18-months. The
analytical time horizon for costs and life years among HIV-
infected children in the absence of ART ran from birth until all
children died or started therapy.
In all strategies, HIV-uninfected children were assumed to have
the same probability of routine HIV diagnosis and exit the model
at time of diagnosis or at 18-months if undiagnosed. They
contributed only to the cost of EID and incurred no mortality as
we assumed their survival to be unaffected by the different
strategies.
Markov Model
HIV-infected children diagnosed and initiating ART entered
the Markov model in one of the following three live states which
represents their disease status at start of therapy:
N Asymptomatic/Mild: CD4.25% if ,35 months or CD4.
15% if $36 months or Centre of Disease Control (CDC)
clinical stage N or A
N Advanced: CD4 15–25% if ,35 months, 7–15% if $36
months or CDC clinical stage B
N Severe: CD4,15% if ,35 months, ,7% if $36 months or
CDC clinical stage C
The model was based on monthly cycles with a probability of
remaining in the same health state, advancing to more severe
health state or death. We assumed non reversibility of health states
Figure 2. Markov model for HIV diagnosis and treatment strategies.
doi:10.1371/journal.pone.0091004.g002
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as children starting ART at more advanced disease stage are at
higher risk of mortality during the first year of therapy [4,6,9],
have lower probability of long-term immune reconstitution and
experience longer duration in immunocompromised state despite
ART [20,21].
The probability of death on ART by health state was based on
the PHPT cohort (NCT00433030) with a median 5-years of follow
up on therapy (described below) [9], and extrapolated using a
Weibull distribution. The model projected unrealistically high
long-term survival on therapy, most likely due to lack of treatment
failures and long-term mortality captured during the follow up
time. To allow for this, we assumed that after five years of ART,
children in the advanced and severe disease stage had a probability
of failing their first and second line therapy and progressing to the
‘Third line ART’ state, with a higher risk of mortality to reflect the
increased risk of sub-optimal adherence and viremia over time on
therapy. Children in the asymptomatic/mild stage were assumed
to experience disease progression before progressing to Third line
ART. The Markov model ran for up to 40 years on ART.
Population
As much as possible the modelling was based on data from
Thailand, primarily from the PHPT paediatric observational
cohort study, which has been described elsewhere [9,22]. In brief,
HIV-infected children were enrolled through two modes of entry.
First was the Birth cohort, children born to HIV-infected mothers
enrolled in clinical trials on PMTCT [23,24] received EID at birth
and at 6 weeks, HIV-infected children initiated ART based on
WHO 2006 immune/clinical criteria [16]. Second was the
Referred cohort: children without access to EID, who were
diagnosed after presentation with HIV symptoms or through
routine serology testing $18 months, they also initiated ART
based on immune/clinical criteria. Due to limited data on long-
term survival based on the Early-Early diagnosis and immediate
ART strategy as part of routine care, this was modelled based on
data from the CHER trial [10].
Input Parameters
Key input parameters are shown in Table 1. Coverage of EID
using DNA PCR on DBS were based on data from the Thai
national EID programme [15,25].
Survival Estimates and Disease Progression
Survival among untreated HIV-infected children was based on
natural history data from the Birth cohort with children censored
at date of death, last seen alive or start of ART, whichever was
earliest (Table S1 in File S1). Due to few children alive and
untreated after 2-years of age, the survival estimates after 2-years
were based on adult natural history survival [26].
Survival estimates in HIV-infected children receiving ART
were based on the Birth cohort for the Early-Late strategy and the
Referred cohort for the Reference strategy. In both strategies, risk
of death was highest during the first year of therapy and declined
to low levels thereafter. Risk of mortality was substantially higher
in children initiated on ART based on clinical/immune criteria ,
12-months old (rapid progressors) as compared to older children
who survived infancy without ART (slow progressors). To reflect
this we weighted the experience of two subgroups (under and over
12-months at start of ART) to create a base case (Table S2 in File
S1). In the Early-Early strategy, where infants receive immediate
ART upon diagnosis, it is unknown what proportion of children
would have been rapid or slow progressors, and this is likely to
vary across settings according to different distributions of in-utero
and intra-partum transmission [26–29]. We assumed a 50:50
distribution and in sensitivity analysis we tested different distribu-
tion assumptions. In the CHER trial, the 76% risk reduction in
mortality observed in the immediate treatment strategy was driven
by the reduction in pre-ART death (among untreated children)
which is captured in the decision tree. There was no evidence of a
difference in mortality after the start of therapy [10], therefore no
reduced risk of mortality on ART was applied to the early-early
strategy of the Markov model. However, a risk reduction on
disease progression was applied for the first 12 months of therapy
to reflect the results of the CHER study’s 40 weeks follow up after
the start of immediate ART.
The distribution of disease stage at start of therapy in the
Reference and Early-Late strategies was based on that observed in
the PHPT cohort (Table 1). The distribution in the Early-Early
strategy was based on the Birth cohort with the risk reduction in
disease progression of 0.24 observed in the CHER study applied to
children in the Advanced and Severe stages starting ART ,12-
months-old. Although CDC stage B and C and CD4,25% were
exclusion criteria in the CHER study, we wanted to allow for the
natural disease progression in the pre-ART period to occur to
avoid over-estimating the benefits of the intervention. Indeed, in
the CHER trial, 22.5% of children were excluded from
randomization (,12 weeks old) due to advanced disease at
screening (2.9% CDC stage C, 19.6% had CD4,25%), who may
still benefit from early treatment in routine care and therefore
were included in the model.
Cost Parameters
The cost estimates used in this model are listed in Table 2. All
costs were adjusted for inflation for Thailand up to 2011 and
converted to US dollars using purchasing power parity (17.5 baht
per international US dollar) [30]. As much as possible costs were
based on data from the PHPT cohort (EID, hospitalization and
ARV drug costs). The unit cost of EID was based on DNA PCR
in-house assays [19], estimated at $57.14 (1000 baht) per test
including cost of initial investment in equipment, reagents, DBS,
transportation costs (DBS transported by regular postal mail),
human resources and maintenance of equipment [25]. Standard
serology test was estimated at $1 per test [31]. Mean cost of
antiretroviral drugs (first, second and third line regimens) was
based on annual average cost observed [19]. Cost of hospitaliza-
tion of children on ART varied according to disease stage during
the first year of therapy, and a mean cost thereafter [22]. The cost
of pre-ART death was assumed to be equal to the cost of
hospitalization during the first year of therapy of a child in the
severe disease stage, as observed in adult studies [32]. We did not
apply a cost of death on ART as we assumed this to be already
incorporated in the hospitalization cost estimates.
Model Validation, Cost-effectiveness and Sensitivity
Analyses
Model validation was based on model projections of survival at
1 and 5 years of ART as compared to the PHPT cohort data for
the Early-Late and Reference strategies.
The modelled costs and outcome, in terms of life years gained
were discounted at 3% per year [33]. We report the projected
discounted and undiscounted life expectancy per HIV infected
child, discounted total programme costs and lifetime costs per HIV
infected child were compared across the three strategies. The
incremental cost-effectiveness ratio (ICER) was defined as
difference in discounted total programme cost divided by
difference in discounted total life years gained (LYG). An ICER
of less than one times the Gross Domestic Product (GDP) per
Cost-Effectiveness of Infant HIV Diagnosis and ART
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capita for Thailand (US $4,420 in 2011, [30]) was considered as
cost effective [34].
We conducted deterministic univariate sensitivity analysis using
the high and low estimates of key input parameters to assess the
impact on the cost-effectiveness estimates. Best and worse-case
scenarios were assessed using high and low estimates of perinatal
transmission combined with current and high estimated costs of
EID and ART.
Probabilistic sensitivity analysis taking into account uncertainty
of all input parameters was conducted using a Monte Carlo
simulation with 1,000 random draws from the specified parameter
distribution. Cholesky decomposition of the variance-covariance
matrices was used to capture correlation between coefficients in
the regression model for mortality on ART [35]. The results are
presented in cost-effectiveness acceptability curves which represent
the probability of the interventions being cost effective at various
willingness to pay thresholds. In addition, sub-group analyses were
conducted to assess the cost-effectiveness of the interventions by
varying levels of access to PMTCT services and risk of perinatal
transmission.
Results
Model Validation
Projected survival at 1 and 5 years of ART in the Reference and
Early-Late strategy were compared to the survival estimates in the
PHPT cohort according to age at start of therapy. Among children
initiated on ART under 12-months old, the model projected
poorer survival as compared to that observed in PHPT cohort, but
projections were within the 95% confidence interval of the survival
estimate, most likely due to the small sample size in this age
group(Table S3 in File S1). Among children initiated on ART
after 12-months of age, projected survival was within 2% of that
observed in the PHPT cohort.
Projected Life Expectancy and Cost-effectiveness
In the reference strategy, the discounted life expectancy of an
HIV-infected child was 13.3 years (undiscounted, 21.0 years), with
a discounted lifetime cost of $17,335 per child. In the Early-Late
strategy, the life expectancy increased to 14.3 years (undiscounted
22.8 years), with a lifetime cost of $22,583 per child. In the Early-
Table 1. Input parameters.
Estimate Distribution Source
Perinatal HIV transmission and coverage of HIV diagnosis
Rate of mother to child transmission
of HIV in Thailand
3.9% (95% CI, 2.2–6.6) Beta [36].
Coverage of early infant HIV diagnosis 68% (range 47–79). Normal [15], Range [14]
Confirmation of EID 78% (range 47–85) Normal [15], Range [17]
Linkage to HIV care within 3 months of
early diagnosis
73.1% (95% CI,64–82) Beta [25]
Initiated ART within 3 months of linkage to HIV care 85.4% (range 79–92) Beta [25]
Coverage of clinical diagnosis ,18 months among
symptomatic
80% (range 70–90) Assumption
Coverage of serology testing .18 months among
symptomatic
95% (range 90–97) Assumption
Coverage of routine serology testing at 18 months 75.8% (range 70–80) [36], Range assumption
Probability of developing symptoms when untreated (monthly)
Probability of developing symptoms ,12-months
when untreated
6.4% (95% CI, 5.5–7.2) Beta [29]
Probability of developing symptoms between
12–23 months when untreated
3.2% (range, 2.8–3.6) Assumption based on half rate of ,12 months.
Distribution of disease stage at start of ART by strategy
Reference strategy: Under 12 months; Over
12 months
A: 8%; 8%; B: 31%; 24%;
C: 62%; 67%
Dirichlet PHPT Referred cohort
Early-late strategy: Under 12 months; Over
12 months
A: 28%; 26%; B: 43%; 40%;
C: 28%; 34%
Dirichlet PHPT Birth cohort
Early-early strategy: Under 12 months; Over
12 months
A: 66%, 26%; B: 27%, 40%;
C: 7%, 34%
Dirichlet Assumption: based on PHPT Birth
cohort* CHER study risk ratio 0.25
in ,12 months [10]
Monthly probability of disease progression on ART
Stage A to B 0.43% [61]
Stage A to C 0.08%
Stage B to C 0.14%
Stage B or C to third line after 5 years
of ART
0.83% PHPT cohort
Third line to death [62]
Risk reduction in disease progression 0.25 (95% CI, 0.15–0.41) [10]
Note: EID; early infant HIV diagnosis, ART; antiretroviral therapy, CDC; centre of disease control.
doi:10.1371/journal.pone.0091004.t001
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Early strategy, the life expectancy increased further to 17.8 years
(undiscounted 29.1 years), with a lifetime cost of $29,108.
The Early-Late strategy had an incremental cost-effectiveness
ratio of $5,149 per LYG as compared to the Reference strategy
(Table 3). The Early-Early strategy had an ICER of $2,615 per
LYG compared to the Reference strategy and $1,873 per LYG
compared to the Early-Late strategy. The Early-Late strategy was
extendedly dominated as compared to Early-Early strategy and
therefore was not considered further (Figure S1 in File S1).
Based on the assumption of 6,000 HIV infected pregnant
women delivering in Thailand per year and an overall risk of
mother to child transmission of HIV of 3.9%, the total discounted
programme cost was estimated at $4.0 million in the Reference
strategy and increases to $6.8 million in the Early-Early strategy
(Table 3). However, over 90% of the total cost of the Early-Early
strategy was attributed to lifetime cost of ART for HIV infected
children and less than 10% on the early infant HIV diagnosis
component for all HIV-exposed infants.
Sensitivity Analyses
In univariate sensitivity analysis, the ICER of the Early-Early
strategy was most sensitive to the discount rate, the cost of
antiretroviral drugs, laboratory monitoring, cost of EID and rate
of perinatal HIV transmission (Figure S2 in File S1). However,
under all scenarios the ICER remained under $4,500 per LYG.
These results were supported by the probabilistic sensitivity
analysis allowing for uncertainty of all model parameters, the
cost-effectiveness acceptability curve show a 99% probability of
the Early-Early strategy being cost effective at $4,500 per LYG
(Figure S3 in File S1).
In sub-group analyses, the cost-effectiveness of the Early-Early
strategy was assessed according to varying levels of coverage of
prophylaxis for PMTCT and risk of perinatal transmission as
observed in Thailand [36]. The Early-Early strategy was most cost
effective among children at highest risk of HIV infection, i.e. those
who received no PMTCT, with 37.5% risk of perinatal
transmission. The ICER of the Early-Early intervention in this
population was $2,248 per LYG as compared to the Reference
strategy. With improved prophylaxis for PMTCT and reduced risk
of perinatal transmission, the ICER increased slightly, but the
Table 2. Cost parameters.
Costs (2011 US$) Unit cost Source
Pre and post HIV test counselling
HIV positive result $9.53 (range 5.02–19.12) [38]
HIV negative result $3.61 (range 2.06–10.24)
Cost of HIV diagnosis per test
Early infant HIV diagnosis using DNA PCR and dried blood spots $57.14 [25]
HIV rapid test by serology $1 [31]
Mean cost of antiretroviral drugs per child per month
Mean cost during the first five years of therapy (includes first and second line therapy) $61.10 (SE 61.10) [63]
Mean cost after five years of therapy (includes first and second line therapy) $86.30 (SE 86.30) [63]
Third line ART $148.30 (SE 148.30) [63]
Laboratory monitoring on ART $26.09 (SE 26.09) [52] and PHPT unpublished data.
Hospitalization during first year of ART in disease stage A or B $24.9 (SE 24.90) [22]
Hospitalization during first year of ART in CDC stage C $43.0 (SE 43.0) [22]
Hospitalization after first year of ART (all disease states) $5.20 (SE 5.20) [22]
Note. All cost estimates were adjusted for inflation up to 2011.
doi:10.1371/journal.pone.0091004.t002
Table 3. Cost and cost-effectiveness of the intervention strategies.
Programme model Reference Early-Late Early-Early
Cost of HIV Diagnosis & pre-ART death $23,754 $454,010 $458,433
Cost of ART including hospitalization $4,009,804 $4,800,673 $6,314,682
Total Cost (All children) $4,033,558 $5,254,683 $6,773,115
Total LY (HIV+child) 3,086 3,323 4,134
Incremental cost-effectiveness ratio per LY over Reference – $5,149 $2,615
Incremental cost-effectiveness ratio per LY over Early-Late – – $1,873
Note: Model assumes 6,000 children born to HIV infected mothers with a risk of HIV transmission of 3.9% and provision of lifelong ART among HIV infected children
diagnosed and initiated on therapy. All costs converted to USD using purchasing power parity (17.5 baht per international US dollar).
doi:10.1371/journal.pone.0091004.t003
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Early-Early strategy remained cost effective as compared to the
Reference strategy at under $4,500 per LYG across all sub-groups
(Figure 3).
In multi-way sensitivity analysis, we assumed the overall
perinatal HIV transmission rate reduced to a target rate of 1.5%
with the introduction of universal HAART for PMTCT [37], high
estimates of EID coverage, confirmation and linkage to ART and
current cost of EID and ART. In this scenario, the ICER
increased to $3,470 per LYG, while the total programme cost
reduced to $3.0 million due to fewer HIV-infected children
requiring lifetime ART.
Discussion
In this study we modelled the survival and costs of providing
EID using DNA PCR and immediate or deferred initiation of
ART in HIV infected children aged ,24-months as compared to
late HIV diagnosis based on clinical status or serology at 18-
months and deferred initiation of ART based on clinical and
immune criteria in the Thai setting. The EID and immediate ART
strategy increased the discounted life expectancy of HIV infected
children from 13.3 to 17.8 years, at an incremental cost-
effectiveness ratio of $2,615 per LYG in the base case. This is
approximately half of Thailand’s GDP per capita and would be
considered as cost effective under WHO recommendations [34].
Importantly, these estimates were made by converting all costs
to US dollars using purchasing power parity (17.5 baht per
international USD). If we had used market exchange rates (34.3
baht per USD) as in other studies [38], with the rationale that the
majority of costs are attributed to imported antiretrovirals and
laboratory assays that are subject to market exchange rates, then
the Early-Early strategy would have even lower incremental cost-
effectiveness ratio and lower programme costs (Table S4 in File
S1).
The benefits of the Early-Early strategy were observed in two
main areas. Firstly, EID and immediate ART minimized the
period in which HIV-infected children were untreated during
infancy, resulting in a halving of pre-ART deaths from 42% in the
Reference strategy down to 21% in the Early-Early strategy. This
figure is not lower due to existing gaps in EID coverage and
referral of HIV infected infants for ART initiation (data not
shown). Second was the reduction in early mortality on ART due
to fewer children initiating therapy at advanced disease stage. The
cost-effectiveness estimate of this strategy is likely to be under-
estimated as we assumed the benefit of immediate ART in
reducing disease progression would only persist for the first year of
therapy, based on the follow up duration of the CHER trial. It is
likely that the benefits are longer lasting due to the preservation of
the immune system; children are better able to maintain good
long-term immunologic response to ART as reported in observa-
tional cohorts of infants who initiated therapy during the first 3
months of life while asymptomatic in Europe and the US [39,40].
Furthermore, we have not taken into account the benefits of
averting damage to cognitive function and neurological develop-
ment among children who progress to advanced disease when left
untreated[41–44], nor have we included the benefits in terms of
quality of life, of accessing early infant HIV diagnosis among HIV-
uninfected infants.
The Early-Late strategy where EID was provided but ART
deferred till after meeting clinical and immune criteria, as
conducted in the PHPT birth cohort prior to WHO 2008
guidelines, was less cost effective when compared to the Reference
Strategy. It resulted in a limited increase in the discounted life
expectancy of HIV infected children (from 13.3 years in the
reference strategy to 14.3 years). This is most likely due to the
limited impact on reducing pre-ART deaths among infants who
have high risk of rapid disease progression and death even at high
CD4% [45], with no prior signs and symptoms [10,29]. In
addition, infants who initiate therapy after disease progression
Figure 3. Cost-effectiveness acceptability curve of Early-Early versus Reference strategy by PMTCT prophylaxes and risk of
perinatal transmission.
doi:10.1371/journal.pone.0091004.g003
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remain at higher risk of mortality despite ART [7–9]. This
highlights the importance of effective referral of HIV-infected
infants as soon as they are diagnosed for immediate ART to
maximize the potential benefits of early treatment.
To our knowledge, this is the first cost-effectiveness evaluation
of early infant HIV diagnosis and different treatment strategies in
children. Previous studies have examined the cost and acceptabil-
ity of early HIV diagnosis using DNA PCR in low- and middle-
income countries [17,46,47]. One study examined the cost-
effectiveness of early infant HIV diagnosis using rapid antibody
tests and clinical examination, primarily to screen out HIV-
uninfected children at minimal cost, however that strategy had
poor specificity among infants under 6 months and only assessed
the cost-effectiveness per correct diagnosis and did not consider
provision of ART for infected children [48]. An economic sub-
study in the CHER trial reported that cost of earlier provision of
ART to asymptomatic infants was more than offset by the reduced
cost of inpatient care as compared to the deferred ART strategy,
but did not include the cost of early HIV diagnosis of all exposed
infants [49].
While there is a growing body of literature on the cost-
effectiveness of different treatment strategies in HIV-infected
adults [50], there are only two comparable studies on HIV care in
children. One was on the cost-effectiveness of cotrimoxazole
prophylaxis for prevention of opportunistic infections in untreated
HIV infected children in Zambia ($74 per LYG) [51]. The second
was on cost-effectiveness of virological monitoring and provision of
second line therapy in HIV infected children in Thailand ($3,393
per year of virological failure averted) [52]. The latter is not
directly comparable to our study as we assumed that HIV infected
children on ART received routine CD4 and virological monitor-
ing every 6 months and had access to second and third line
regimen upon treatment failure as per national guidelines [18].
Based on these assumptions, the addition of EID and immediate
treatment in all HIV-infected children ,24-months was cost-
effective, and is likely to be affordable in the Thai setting.
Importantly, if the rate of mother-to-child transmission continues
to decline further with introduction of HAART for PMTCT and
more extensive provision of HAART to HIV-infected adults
(including women during time of conception and pregnancy) [53],
then the total programme cost of this strategy is likely to decrease
over time as fewer children are infected and require lifelong
treatment which accounts for over 90% of the programme costs.
In addition, on-going developments in low cost HIV laboratory
services including EID at point of care in resource-limited settings
are likely to further simplify collection and transportation of
samples and make EID more affordable and feasible for routine
use [54]. Maturing EID programmes have reported innovative
strategies to improve uptake of EID and retention of HIV-exposed
infants, although there remain scarce data on the follow-up and
treatment status of newly diagnosed HIV-infected infants
[15,55,56]. Such indicators are critical for the evaluation of
PMTCT and paediatric HIV programmes and should be
highlighted as an important goal as part of the campaign for a
zero HIV generation.
There are a number of important limitations of this study. First,
the survival estimates of children on ART were extrapolated from
an observational study with five years of follow-up due to scarce
long-term data from a low and middle income setting. Data from
paediatric cohorts in the US or Europe were not used as they
represented a different population with access to earlier treatment
using more potent and costly drugs and lower estimates of
mortality and hospitalization [5,57]. Second, the Markov model of
children on ART assumed non reversibility of health states, as
there remains limited data on long-term immunologic response
and risk of mortality among infants/older children starting therapy
at different disease stages to inform a more complex reversible
model. However, the main benefits of EID and immediate ART
were the reduction in pre-ART deaths and early mortality on
ART, therefore a more detailed model of the long-term survival is
unlikely to affect the overall findings.
Third, this study is based on data largely from the Thai setting
and therefore the findings cannot be extended to other settings
with different coverage of services, mortality rates, costs and
thresholds for cost-effectiveness. Furthermore, this study was based
on a non-breastfeeding population, most of the countries with the
highest burden of HIV in sub-Saharan Africa, recommend
exclusive breastfeeding and thus repeated early infant HIV
diagnosis during the breastfeeding period and after weaning
would be required. Fourth, in this study we assumed 100%
sensitivity and specificity of DNA PCR testing from 2 months of
life – based on data from the PHPT study where children were
exposed to nevirapine and zidovudine prophylaxis for PMTCT. A
study by Shapiro and colleagues suggests that early diagnosis of
infants exposed to maternal or infant HAART for PMTCT may
be less sensitive during the first months of life [58], which may
have important implications for the recommended schedule for
early diagnosis and may require more confirmation tests.
However, when we assumed a doubling in the cost of EID – this
intervention was still cost effective. Lastly, recent reports of a
functional cure of an HIV-infected infant diagnosed and initiated
ART at 30 hours of life in the United States [59] has generated
much interest in the potential benefits of birth testing and very
early ART in preventing seeding of the HIV reservoir [60].
However, the sensitivity of virological tests at birth with DBS and
exposure to maternal HAART are not well described. Also, the
birth test would only identify the in-utero transmissions, and the
feasibility of such rapid return of test results and ART referral in
resource-limited settings has yet to be determined; implementation
studies and cost-effectiveness analyses of a birth test algorithm are
needed to inform future policies and programmes.
Conclusion
Early infant HIV diagnosis combined with immediate ART of
children under 24 months was cost effective in the Thai setting as
compared to late diagnosis and deferred treatment. Expanding
programmes for EID must place greater emphasis on retention of
HIV infected infants identified and timely initiation of ART prior
to disease progression to maximize the benefit in reducing HIV
related morbidity and mortality in this highly vulnerable
population.
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